Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Eugene D Kwon; Charles G Drake; Howard I Scher; Karim Fizazi; Alberto Bossi; Alfons J M van den Eertwegh; Michael Krainer; Nadine Houede; Ricardo Santos; Hakim Mahammedi; Siobhan Ng; Michele Maio; Fabio A Franke; Santhanam Sundar; Neeraj Agarwal; Andries M Bergman; Tudor E Ciuleanu; Ernesto Korbenfeld; Lisa Sengeløv; Steinbjorn Hansen; Christopher Logothetis; Tomasz M Beer; M Brent McHenry; Paul Gagnier; David Liu; Winald R Gerritsen

doi:10.1016/S1470-2045(14)70189-5

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Eugene D Kwon, Charles G Drake, Howard I Scher, Karim Fizazi, Alberto Bossi, Alfons J M van den Eertwegh, Michael Krainer, Nadine Houede, Ricardo Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fabio A Franke, Santhanam Sundar, Neeraj Agarwal, Andries M Bergman, Tudor E Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjorn HansenChristopher Logothetis, Tomasz M Beer, M Brent McHenry, Paul Gagnier, David Liu, Winald R Gerritsen

Universitätsklinik für Radiotherapie und Radio-Onkologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

1231 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	700-712
Fachzeitschrift	LANCET ONCOL
Jahrgang	15
Ausgabenummer	7
DOIs	https://doi.org/10.1016/S1470-2045(14)70189-5
Publikationsstatus	Veröffentlicht - 2014

Zugriff auf Dokument

10.1016/S1470-2045(14)70189-5

Dieses zitieren

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., Ng, S., Maio, M., Franke, F. A., Sundar, S., Agarwal, N., Bergman, A. M., Ciuleanu, T. E., Korbenfeld, E., Sengeløv, L., ... Gerritsen, W. R. (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. LANCET ONCOL, 15(7), 700-712. https://doi.org/10.1016/S1470-2045(14)70189-5

@article{873909792b96441c8bebed2f718303d5,

title = "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.",

keywords = "DOSE-ESCALATION TRIAL, SURVIVAL ANALYSIS, CTLA-4 BLOCKADE, OPEN-LABEL, IMMUNOTHERAPY, MELANOMA, CELLS, ANTIGEN, TIME",

author = "Kwon, \{Eugene D\} and Drake, \{Charles G\} and Scher, \{Howard I\} and Karim Fizazi and Alberto Bossi and \{van den Eertwegh\}, \{Alfons J M\} and Michael Krainer and Nadine Houede and Ricardo Santos and Hakim Mahammedi and Siobhan Ng and Michele Maio and Franke, \{Fabio A\} and Santhanam Sundar and Neeraj Agarwal and Bergman, \{Andries M\} and Ciuleanu, \{Tudor E\} and Ernesto Korbenfeld and Lisa Sengel{\o}v and Steinbjorn Hansen and Christopher Logothetis and Beer, \{Tomasz M\} and McHenry, \{M Brent\} and Paul Gagnier and David Liu and Gerritsen, \{Winald R\}",

note = "Investigator List (Apendix B): Austria - Felix Sedlmayer",

year = "2014",

doi = "10.1016/S1470-2045(14)70189-5",

language = "English",

volume = "15",

pages = "700--712",

journal = "LANCET ONCOL",

issn = "1470-2045",

publisher = "Elsevier ",

number = "7",

}

Kwon, ED, Drake, CG, Scher, HI, Fizazi, K, Bossi, A, van den Eertwegh, AJM, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Maio, M, Franke, FA, Sundar, S, Agarwal, N, Bergman, AM, Ciuleanu, TE, Korbenfeld, E, Sengeløv, L, Hansen, S, Logothetis, C, Beer, TM, McHenry, MB, Gagnier, P, Liu, D & Gerritsen, WR 2014, 'Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.', LANCET ONCOL, Jg. 15, Nr. 7, S. 700-712. https://doi.org/10.1016/S1470-2045(14)70189-5

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. / Kwon, Eugene D; Drake, Charles G; Scher, Howard I et al.
in: LANCET ONCOL, Jahrgang 15, Nr. 7, 2014, S. 700-712.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

AU - Kwon, Eugene D

AU - Drake, Charles G

AU - Scher, Howard I

AU - Fizazi, Karim

AU - Bossi, Alberto

AU - van den Eertwegh, Alfons J M

AU - Krainer, Michael

AU - Houede, Nadine

AU - Santos, Ricardo

AU - Mahammedi, Hakim

AU - Ng, Siobhan

AU - Maio, Michele

AU - Franke, Fabio A

AU - Sundar, Santhanam

AU - Agarwal, Neeraj

AU - Bergman, Andries M

AU - Ciuleanu, Tudor E

AU - Korbenfeld, Ernesto

AU - Sengeløv, Lisa

AU - Hansen, Steinbjorn

AU - Logothetis, Christopher

AU - Beer, Tomasz M

AU - McHenry, M Brent

AU - Gagnier, Paul

AU - Liu, David

AU - Gerritsen, Winald R

N1 - Investigator List (Apendix B): Austria - Felix Sedlmayer

PY - 2014

Y1 - 2014

KW - DOSE-ESCALATION TRIAL

KW - SURVIVAL ANALYSIS

KW - CTLA-4 BLOCKADE

KW - OPEN-LABEL

KW - IMMUNOTHERAPY

KW - MELANOMA

KW - CELLS

KW - ANTIGEN

KW - TIME

U2 - 10.1016/S1470-2045(14)70189-5

DO - 10.1016/S1470-2045(14)70189-5

M3 - Original Article

C2 - 24831977

SN - 1470-2045

VL - 15

SP - 700

EP - 712

JO - LANCET ONCOL

JF - LANCET ONCOL

IS - 7

ER -

Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. LANCET ONCOL. 2014;15(7):700-712. doi: 10.1016/S1470-2045(14)70189-5